Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 3

Sponsor Class

OTHER 9INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Lymphoid 3Plasma cell 2

Conditions

Multiple Myeloma 14Lymphoma, Non-Hodgkin 14Hodgkin Disease 5Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 3Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Neuroblastoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Brain Neoplasms 1

Interventions

Rituximab 63Cyclophosphamide 37Brentuximab Vedotin 22Bendamustine Hydrochloride 22pembrolizumab 20fludarabine 20Gemcitabine 20Doxorubicin 20Prednisone 19ibrutinib 17Vincristine 16obinutuzumab 14Lenalidomide 13Nivolumab 10Rifampin 8parsaclisib 7duvelisib 7atezolizumab 7Vorinostat 7Dexamethasone 7Azacitidine 7spartalizumab 6loncastuximab tesirine 6MLN 8237 6venetoclax 5ixazomib 5glofitamab 5fludarabine phosphate 5durvalumab 5acalabrutinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma × plerixafor × Clear all
NCT02221492 2016-03-30

Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma

Sanofi

Phase 2 Completed
32 enrolled
Lymphoid

Lymphoma

NCT01738373 2015-03-23

Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation

Sanofi

Completed
262 enrolled
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT00665314 2014-02-11

Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).

Sanofi

Phase 2 Completed
5 enrolled
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡